Effect of Nitazoxanide, Artesunate Loaded Polymeric Nano Fiber and Their Combination on Experimental Cryptosporidiosis

Overview

Journal Iran J Parasitol

Publisher Tehran University of Medical Sciences

Specialty Parasitology

Date 2019 Sep 24

PMID 31543912

Citations 10

Authors

Enas Fakhry Abdelhamed

Eman Magdy Fawzy

Said Mahmoud Ahmed

Rabab Sayed Zalat

Hayam Elsaid Rashed

Affiliations

Soon will be listed here.

Abstract

Background: is a dangerous intestinal pathogen due to its devastating effect on immunocompromised individuals. Considering low efficacy, high toxicity in addition to the development of resistance for the drugs used, this study aimed to find a new alternative treatment having the advantage of lower doses and minimal toxicity. We used a novel combination between artesunate loaded polymeric nanofiber (ALPN) and nanazoxide that had not been tried yet.

Methods: Sixty Swiss Albino mice aged 6-7 wk, weighting 20-24 gm were used in Theodor Bilharz Research Institute (TBRI) Cairo, Egypt in 2017. oocysts collected from patients were identified by polymerase chain reaction to be used for infecting animals. The effect of combination between ALPN and nana-zoxide were assessed by oocyst count in stool of experimental animals using modified Ziehl-Neelsen stain and histopathological changes in intestinal tissue. Antioxidant activity of nanofiber-loaded artesunate was estimated in serum, renal, hepatic and intestinal tissues by demonstrating the reactive oxygen species and the total antioxidant capacity. It was confirmed by detection of inducible nitric oxide synthase (iNOS) antibody.

Results: The novel combination between ALPN and nanazoxidehas a harmonizing effect in reducing oocyst shedding (94.4%), the mean value of the antioxidant levels in liver, intestine, kidney, and serum were the highest level (10.15, 22.4, 6.22, 14.08 respectively) resulting in the decrease of oxidative stress in tissues. Marked improvement of histopathological features was obtained.

Conclusion: This combination has a promising therapeutic effect against cryptosporidiosis particularly in immunocompromised individuals considering minor toxicity.

Citing Articles

Evaluation of potential antiparasitic effect of ZnO nanoparticles on experimental cryptosporidiosis in immunosuppressed mice.

Alrefaee S, Aljohani F, El-Khatib M, Shahin Y, Elwakil B, Shahin S Biometals. 2025; .

PMID: 40009283 DOI: 10.1007/s10534-025-00669-7.

Biomaterials for neuroengineering: applications and challenges.

Wu H, Feng E, Yin H, Zhang Y, Chen G, Zhu B Regen Biomater. 2025; 12:rbae137.

PMID: 40007617 PMC: 11855295. DOI: 10.1093/rb/rbae137.

Therapeutic potential of platelet rich plasma against experimental infection: in vivo study in immunosuppressed mice.

Mahmoud N, Younis A, Zalat R, Soliman A, Khater M J Parasit Dis. 2024; 48(4):849-859.

PMID: 39493467 PMC: 11528079. DOI: 10.1007/s12639-024-01713-y.

and evaluation of the anti-cryptosporidial activity of eugenol.

Gattan H, Wakid M, Qahwaji R, Altwaim S, Mahjoub H, Alfaifi M Front Vet Sci. 2024; 11:1374116.

PMID: 38515537 PMC: 10954888. DOI: 10.3389/fvets.2024.1374116.

Medical prospects of cryptosporidiosis control using biofabricated nanoparticles loaded with extracts by .

Allam N, Hamouda R, Sedky D, Abdelsalam M, El-Gawad M, Hassan N Vet World. 2024; 17(1):108-124.

PMID: 38406364 PMC: 10884584. DOI: 10.14202/vetworld.2024.108-124.

References

Brennan P, Conroy B, Spedding A . Expression of inducible nitric oxide synthase and p53 in oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90(5):624-9. DOI: 10.1067/moe.2000.108800. View

Ghiselli A, Serafini M, Natella F, Scaccini C . Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic Biol Med. 2000; 29(11):1106-14. DOI: 10.1016/s0891-5849(00)00394-4. View

Koracevic D, Koracevic G, Djordjevic V, Andrejevic S, Cosic V . Method for the measurement of antioxidant activity in human fluids. J Clin Pathol. 2001; 54(5):356-61. PMC: 1731414. DOI: 10.1136/jcp.54.5.356. View

Hunter P, Nichols G . Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev. 2002; 15(1):145-54. PMC: 118064. DOI: 10.1128/CMR.15.1.145-154.2002. View

Hibbs Jr J . Infection and nitric oxide. J Infect Dis. 2002; 185 Suppl 1:S9-17. DOI: 10.1086/338005. View

Rasmussen K, Healey M . Dehydroepiandrosterone-induced reduction of Cryptosporidium parvum infections in aged Syrian golden hamsters. J Parasitol. 1992; 78(3):554-7. View

Farthing M . Treatment options for the eradication of intestinal protozoa. Nat Clin Pract Gastroenterol Hepatol. 2006; 3(8):436-45. DOI: 10.1038/ncpgasthep0557. View

Smith H, Caccio S, Cook N, Nichols R, Tait A . Cryptosporidium and Giardia as foodborne zoonoses. Vet Parasitol. 2007; 149(1-2):29-40. DOI: 10.1016/j.vetpar.2007.07.015. View

Gargala G . Drug treatment and novel drug target against Cryptosporidium. Parasite. 2008; 15(3):275-81. DOI: 10.1051/parasite/2008153275. View

10.

Ferreira J, Gonzalez J . Analysis of underivatized artemisinin and related sesquiterpene lactones by high-performance liquid chromatography with ultraviolet detection. Phytochem Anal. 2008; 20(2):91-7. DOI: 10.1002/pca.1101. View

11.

Rossignol J . Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp Parasitol. 2009; 124(1):45-53. DOI: 10.1016/j.exppara.2009.07.005. View

12.

Valderrabano J, Calvete C, Uriarte J . Effect of feeding bioactive forages on infection and subsequent development of Haemonchus contortus in lamb faeces. Vet Parasitol. 2010; 172(1-2):89-94. DOI: 10.1016/j.vetpar.2010.04.018. View

13.

Wu L, Jiang X, Shen Y, Lu Z, Tu G, Fu X . Efficacy of ginkgolic acids against Cryptosporidium andersoni in cell culture. Parasitol Res. 2011; 109(5):1475-9. DOI: 10.1007/s00436-011-2433-1. View

14.

Benamrouz S, Guyot K, Gazzola S, Mouray A, Chassat T, Delaire B . Cryptosporidium parvum infection in SCID mice infected with only one oocyst: qPCR assessment of parasite replication in tissues and development of digestive cancer. PLoS One. 2012; 7(12):e51232. PMC: 3521773. DOI: 10.1371/journal.pone.0051232. View

15.

Kotloff K, Nataro J, Blackwelder W, Nasrin D, Farag T, Panchalingam S . Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet. 2013; 382(9888):209-22. DOI: 10.1016/S0140-6736(13)60844-2. View

16.

Kim M, Seo J, Liu K, Kim J . Protective effect of Artemisia annua L. extract against galactose-induced oxidative stress in mice. PLoS One. 2014; 9(7):e101486. PMC: 4079707. DOI: 10.1371/journal.pone.0101486. View

17.

Morie A, Garg T, Goyal A, Rath G . Nanofibers as novel drug carrier--An overview. Artif Cells Nanomed Biotechnol. 2014; 44(1):135-43. DOI: 10.3109/21691401.2014.927879. View

18.

Andrews K, Fisher G, Skinner-Adams T . Drug repurposing and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist. 2014; 4(2):95-111. PMC: 4095053. DOI: 10.1016/j.ijpddr.2014.02.002. View

19.

Checkley W, White Jr A, Jaganath D, Arrowood M, Chalmers R, Chen X . A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis. 2014; 15(1):85-94. PMC: 4401121. DOI: 10.1016/S1473-3099(14)70772-8. View

20.

Garg T, Rath G, Goyal A . Biomaterials-based nanofiber scaffold: targeted and controlled carrier for cell and drug delivery. J Drug Target. 2014; 23(3):202-21. DOI: 10.3109/1061186X.2014.992899. View